LifeScan's blood-glucose monitoring system receives FDA clearance

LifeScan, one of Johnson & Johnson's diabetes care companies, has received U.S. Food and Drug Administration (FDA) clearance for the integration of its wireless OneTouch Verio Flex blood glucose monitoring system with WellDoc's BlueStar diabetes management platform.

The technology features a built-in meter that simplifies the results of blood-sugar testing. The pairing of OneTouch’s blood glucose monitoring system with WellDoc’s diabetes management platform provides patients the ability to receive personalized real-time feedback and virtual coaching. It will help physicians make more informed decisions regarding a patient’s information. Along with web and mobile application, the pairing makes a complete, data-driven and payer-reimbursed program for patients with type 2 diabetes.

"Our partnership with WellDoc highlights our sustained commitment in helping to drive better health outcomes by building a more connected patient experience. Integrating digital solutions such as OneTouch Reveal® mobile app and BlueStar will help patients self-manage their diabetes and create value for health care providers," said Valerie Asbury, president of LifeScan.